Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Joyce Liu, MD
Study ID
NCT06369155
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Azenosertib — DRUG
    Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.

Study Details

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)

Key Dates

Start date
Mar 5, 2025
Status verified
Feb 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2028

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Azenosertib
    25 participants will be enrolled and will complete study procedures as follows: * Baseline visit with assessments and CT or MRI scan. * CT or MRIs scans every 2 cycles. * Cycle 1 through End of Treatment: --Days 1 through 5, 8 through 12, and 15 through 19: Predetermined dose of Azenosertib 1x daily. * End of Treatment visit.

Primary Outcome Measure

Percentage Change in Replication Fork Speed in Overall Response [ Time Frame: Up to 7 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02215
Joyce Liu, MD, MPH
[email protected]
617-632-5269
Joyce Liu, MD, MPH (PRINCIPAL_INVESTIGATOR)
Dana-Farber Cancer InstituteBostonMassachusetts02215
Joyce Liu, MD, MPH
[email protected]
617-632-5269
Joyce Liu, MD, MPH (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Brigham and Women's Hospital· Boston, MADana-Farber Cancer Institute· Boston, MA

Related Studies